PNC Financial Services Group
PRLD icon

PNC Financial Services Group’s Prelude Therapeutics PRLD Stock Holding History

PNC Financial Services Group’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.24K Hold
1,171
– – ﹤0.01% 4306
2026
Q1 		$4K Hold
1,171
– – ﹤0.01% 4362
2025
Q4 		$3.4K Hold
1,171
– – ﹤0.01% 4376
2025
Q3 		$1.69K Sell
1,171
-9
-0.8% -$9 ﹤0.01% 4552
2025
Q2 		$956 Sell
1,180
-12
-1% -$10 ﹤0.01% 4574
2025
Q1 		$915 Buy
1,192
+1,128
+1,763% +$1.05K ﹤0.01% 4539
2024
Q4 		$82 Hold
64
– – ﹤0.01% 4718
2024
Q3 		$132 Hold
64
– – ﹤0.01% 4707
2024
Q2 		$244 Buy
+64
New +$260 ﹤0.01% 4635

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

PNC Financial Services Group's PRLD Position: Q2 2026 in Review

PNC Financial Services Group held its Prelude Therapeutics (PRLD) position steady in Q2 2026 at 1,171 shares worth $6.24K. The position accounts for ﹤0.01% of the portfolio, ranked #4306.

PNC Financial Services Group first reported a position in PRLD in Q2 2024 and has held it in 9 quarters since. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • PNC Financial Services Group held 1,171 shares of Prelude Therapeutics worth $6.24K as of Q2 2026.
  • PNC Financial Services Group left its Prelude Therapeutics share count unchanged in Q2 2026.
  • Prelude Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #4306 holding.
  • PNC Financial Services Group first reported a position in Prelude Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.